 |
|
|
|
 |
|
|
| Article 1 to 10 out of 59 concerning Evotec AG
|
-
Evotec Signs High Throughput Screening Agreement with Active Biotech
(15 Mar 2010)
Evotec AG announced that it has entered into a collaboration with Active Biotech AB to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer.Evotec will use its ...
-
Evotec Reports Good Progress in Product Development in Treatment-Resistant Depression in its Alliance with Roche
(12 Mar 2010)
Successful completion of first-in-man study with EVT 103
Evotec AG announced two positive aspects that strengthen its integrated product development in treatment-resistant depression in its strategic alliance with Roche. Evotec AG completed the clinical part of the first Phase I study with its ...
-
Evotec and Vifor Pharma Sign Major Cooperation Agreement
(03 Feb 2010)
Development of preclinical candidate in the field of anaemia
Evotec AG announced that it has signed an agreement with Vifor Pharma. Evotec will provide and project manage the discovery activities to identify a preclinical candidate for the treatment of anaemia. Due to confidentiality reasons both companies ...
-
Evotec and CHDI Foundation, Inc. Extend Collaboration to Fight Huntington’s Disease
(18 Jan 2010)
Evotec AG announced the extension of its collaboration with CHDI Foundation, Inc. (CHDI) through to the end of 2012. The collaboration, which is aimed at finding new treatments for Huntington’s disease and represents one of the largest joint ...
-
Evotec Achieves Milestone in Medicinal Chemistry Collaboration with Ono Pharmaceutical Co., Ltd.
(16 Dec 2009)
Evotec receives milestone from Ono for the progression of novel protease inhibitors into lead optimisation
Evotec AG announced that it has received a milestone payment from Ono Pharmaceutical Co., Ltd. (Ono) from its research collaboration aimed at identifying novel inhibitors for a protease target. The milestone is received for the progression of the ...
-
Evotec Wins German Government Research Grant
(18 Nov 2009)
Evotec announced that it has been granted up to €2.5 m in research funds from the BMBF, within the Neu2 consortium, to advance research and development activities on the target Serine Racemase for potential use in neuroprotection. Evotec will use ...
-
Evotec and Boehringer Ingelheim Extend and Broaden Research Collaboration
(10 Nov 2009)
Strategic research collaboration continues for another 4 years at a value of EUR 15 million plus milestones and royalties
Evotec AG announced that it has extended the research collaboration with Boehringer Ingelheim for a further 4 years. The collaboration was initiated in August 2004 and has been extended on two previous occasions. At the same time, based on the ...
-
Evotec Receives a EUR 2.5 Million Milestone Payment in its Research Collaboration with Boehringer Ingelheim
(23 Oct 2009)
Evotec AG announced that it has achieved another milestone in its research collaboration with Boehringer Ingelheim. The collaboration, which was initiated in August 2004, has up to now resulted in seven milestone payments. The achievement of the ...
-
Evotec Signs Agreement with DiscoveRx Corporation to Support High Throughput Screening Services
(21 Oct 2009)
Evotec AG and DiscoveRx Corporation announced a co-marketing agreement for the screening of GPCR’s and other targets. Under the terms of the agreement, Evotec will have access to DiscoveRx’s PathHunter™ and cAMPHunter™ cell lines and proprietary ...
-
Evotec Extends Medicinal Chemistry Collaboration with Ono Pharmaceutical
(16 Oct 2009)
Evotec AG announced that it has extended its current research collaboration with Ono Pharmaceutical Co., Ltd. (Ono) and initiated a new discovery collaboration. Under the contract extension Evotec will provide integrated drug discovery activities, ...
Additional information
Evotec AG
Hamburg, Germany
Company
|
|
|
|
|
|
Top
